AIM at Melanoma - Reshaping the Future Together

A World Untouched by Melanoma

Our goal at AIM at Melanoma is for the words, “You have melanoma,” to be forever removed from our vocabularies. Is that too much to hope for? We don’t think so.

Clinical Trials

Through participation in these trials, patients may receive access to new therapy options that are not available to melanoma patients outside the clinical trial setting.

Find a Clinical Trial

Melanoma Concierge

We’re committed to giving you and your loved ones the tools you need to cope with and battle this disease.

Our Melanoma Outreach Services

Melanoma Kills One Person Every 54 Minutes

AIM is boldly doing something that no other research institution, foundation or medical center has done for melanoma.

The Time Is Now

Walks & Fun Runs

Help us increase melanoma awareness and raise money to support research.

Research

Groundbreaking

Research

Research

Education & Support

Stages of Melanoma

Stage 0 (in situ)

Research

Reshaping the Future Together

Fundraising

AIM Walks & Fun Runs

AIM Fundraisers & Partner Programs

Speak with our Oncology Nurse

Here for you. When you need answers. Free of Charge. 100% confidential.

I Have a Question

or call 1-877-246-2635

Search for a Melanoma Specialist

Clinical Trials Matching Service

Melanoma Education

From risk factors, to melanoma stages, to treatment, and beyond

Innovative Research

Changing the face and future of melanoma research to discover the CURE

Global Engagement & Advocacy

Most influential voice in melanoma, locally and globally

Leading the Way in Legislation

Leading and winning legislative and regulatory change across the country

Melanoma News & Events

News 11/29/2018

AIM awards $25,000 Research Grant to MD Anderson Cancer Center (MDACC)

News 11/14/2018

AIM at Melanoma’s International Melanoma Working Group: Progress Report

News 11/13/2018

President’s Message – November 2018

News 11/13/2018

Melanoma International Collaborative Adaptive Trials: Progress Report

News 11/13/2018

Melanoma Legislation: Progress Report

News 11/13/2018

Melanoma Education: Progress Report

News 11/13/2018

Global Advocacy: Progress Report

News 11/13/2018

The Melanoma Tissue Bank: Progress Report

News 10/22/2018

First-Line Nivolumab Alone or With Ipilimumab Continues to Show Durable Survival Benefits in Advanced Melanoma

News 10/22/2018

Pembrolizumab With Dabrafenib and Trametinib Shows Efficacy, But High TRAEs, in Melanoma

News 10/22/2018

Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600–Mutant Stage III Melanoma

News 10/21/2018

Dynavax's SD-101 in Combination with KEYTRUDA(R) (pembrolizumab) Continues to Show a 70% Overall Response Rate in Advanced Melanoma Patients

Please keep me informed.

Receive comprehensive, breaking news about melanoma, research, legislation, and events.

First Name*
Last Name*
Email*
Address*
State / Province / Region ZIP / Postal Code Country
Name
This field is for validation purposes and should be left unchanged.